Key findings include: Mean weight loss of 24.2% (approximately 58 pounds or 26.2 kg) with 12 mg weekly dose after 48 weeks Dose-dependent efficacy across 1 mg, 4 mg, 8 mg, and 12 mg dose groups At 48 weeks, 100% of participants receiving 8 mg or 12 mg achieved at least 5% weight loss 93% of participants on 12 mg achieved 15% or more weight loss , far exceeding current therapeutic benchmarks Greater weight reduction observed in participants with BMI greater than or equal to 35 compared to those with BMI below 35 The magnitude of weight loss approaches that typically observed only with bariatric-metabolic surgery, representing a potential paradigm shift in pharmacological obesity treatment[11]
it's the nature of dispensed prescription medication
(Notably, this NMDA co-agonist function underlies research into glycine for neuro-psychiatric conditions
David Ghozland, MD of David Ghozland, MD Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Glucagon Receptor Engagement Energy Expenditure and Hepatic Metabolism Although GLP3 exhibits lower potency at glucagon receptors compared to native glucagon, this component of its triagonist mechanism appears critical for its metabolic effects[8]: Increased energy expenditure through thermogenic activation Enhanced hepatic fatty acid oxidation and reduced hepatic steatosis Modulation of hepatic glucose production during fasted states Promotion of lipolysis in adipose tissue Potential effects on lean mass preservation through metabolic adaptations In vitro studies demonstrated that GLP3 achieves efficacy similar to natural glucagon in stimulating glucose production in hepatocytes, while in adipocytes it surpasses native GIP in inducing lipolysis[9]
GLP-1 receptor agonists work like the naturally produced hormone, GLP-1
